Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noctura 400 for Diabetic Macular Oedema
NCT02207712Terminated
- Sponsor
- PolyPhotonix
- Start
- Nov 2014
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by PolyPhotonix. Primary endpoint: Number of intravitreal injections of ranibizumab required at 48 weeks. Started Nov 2014; status: terminated.
Beyond the preview
Go deeper on NCT02207712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207712.